Research programme: breast cancer therapeutics - Bayer HealthCare Pharmaceuticals
Latest Information Update: 04 Nov 2017
Price : $50 *
At a glance
- Originator Berlex Biosciences
- Developer Bayer HealthCare Pharmaceuticals Inc.
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Breast-cancer in USA
- 19 Feb 2009 Preclinical development is ongoing in USA
- 04 Apr 2007 Berlex is now called Bayer HealthCare Pharmaceuticals